MGIM
SRPT icon

M&G Investment Management’s Sarepta Therapeutics SRPT Stock Holding History

M&G Investment Management’s Portfolio SRPT Stock Details SRPT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q1 		– Sell
-28,562
Closed -$3.71M – 470
2022
Q4 		$3.71M Buy
28,562
+13,076
+84% +$1.52M 0.02% 236
2022
Q3 		$1.72K Buy
+15,486
New +$1.56M 0.01% 257

Other funds holding SRPT

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

M&G Investment Management's SRPT Position: Q1 2023 in Review

M&G Investment Management sold out of Sarepta Therapeutics (SRPT) in Q1 2023, closing a stake of 28,562 shares — an estimated $3.71M sold.

M&G Investment Management first reported a position in SRPT in Q3 2022 and held it in 2 quarters. The position peaked at $3.71M in Q4 2022. 425 funds tracked by Wall St. Rank hold SRPT as of Q1 2023.

  • M&G Investment Management reported no remaining Sarepta Therapeutics position as of Q1 2023 after selling out during the quarter.
  • M&G Investment Management sold 28,562 Sarepta Therapeutics shares in Q1 2023, an estimated $3.71M.
  • M&G Investment Management first reported a position in Sarepta Therapeutics in Q3 2022 and held it in 2 quarters.
  • M&G Investment Management's Sarepta Therapeutics position peaked at $3.71M in Q4 2022.
  • 425 funds tracked by Wall St. Rank held Sarepta Therapeutics as of Q1 2023.

Based on M&G Investment Management's 13F filing for Q1 2023, filed 11 May 2023.